NRSG 2350 Exam 2 Meds 2025-2026
QUESTIONS AND VERIFIED ANSWERS
ALREADY GRADED A+
ferrous sulfate - WHY: treatment for IDA
MOA: Replaces serum iron concentration for hemoglobin production
ADE: constipation, darkened stool, staining of teeth, NVD
CI: children toxicity, hemochromatosis, peptic ulcers
D-D: antacids, tetracyclines, ascorbic acid
cyanocobalamin (synthetic form of B12) - WHY: pernicious anemia, essential for cell growth and division
- necessary for myelin sheath
MOA: replacement of essential vitamin B12
ADE: NVD, injection site reaction, itching
CI: alleries, thickened blood
folic acid (vitamin B9) - WHY: folic acid deficiency anemia, prophylaxis during pregnancy (prevent neural
tube defects)
MOA: water soluble, essential for cell growth and division, replacement of essential vitamin
ADE: NVD, no known because it is something we already have
CI: allergy, methotrexate
hydroxyurea (droxia) - WHY: sickle cell anemia, increase fetal hemoglobin in the bone marrow
MOA: increase fetal hemoglobin in the bone marrow
ADE: NVD, HA, disorientation, chills, increase risk of cancer, bone marrow suppression
CI: allergy, severe anemia / leukopenia, pregnancy, liver/kidney impairment
, D-D: warfarin, uricosuric agents
epoetin alfa (Epogen), erythropoiesis stimulating agent - WHY: treat anemia of chronic disease, reduce
the need for pRBC transfusions
MOA: stimulates bone marrow to make more RBCs (erythropoiesis)
ADE: seizures, HA, dizzy, NVD, HTN, edema, chest pani
CI: uncontrolled HTN
D-D: do not mix with other drugs
antihemophilic - WHY: replace factor VIII in patients with hemophilia A, prevent blood loss from injury,
surgery or to treat disorder
MOA: replaced blood clotting factors - genetically missing or low
ADE: HA, flushing, chills, lethargy, NV, site reaction
CI: allergy, inhibitors of factor VIII, factor IX with liver disease, lactation
antiocoagulants - -prevents clots and prevents from getting bigger
-does not get rid of a clot
- heparin
- warfarin
heparin - - suppresses intrinsic pathway
- monitor PTT levels every ~4-6 hours
- IV: bolus then continuous drip; unfractional
- SQ: LMW, doesn't require monitoring of PTT levels at low doses
- inactivator: protamine sulfate
- therapeutic action within seconds
- dosing is weight based
low molecular weight heparins - - more predictable and longer half life
QUESTIONS AND VERIFIED ANSWERS
ALREADY GRADED A+
ferrous sulfate - WHY: treatment for IDA
MOA: Replaces serum iron concentration for hemoglobin production
ADE: constipation, darkened stool, staining of teeth, NVD
CI: children toxicity, hemochromatosis, peptic ulcers
D-D: antacids, tetracyclines, ascorbic acid
cyanocobalamin (synthetic form of B12) - WHY: pernicious anemia, essential for cell growth and division
- necessary for myelin sheath
MOA: replacement of essential vitamin B12
ADE: NVD, injection site reaction, itching
CI: alleries, thickened blood
folic acid (vitamin B9) - WHY: folic acid deficiency anemia, prophylaxis during pregnancy (prevent neural
tube defects)
MOA: water soluble, essential for cell growth and division, replacement of essential vitamin
ADE: NVD, no known because it is something we already have
CI: allergy, methotrexate
hydroxyurea (droxia) - WHY: sickle cell anemia, increase fetal hemoglobin in the bone marrow
MOA: increase fetal hemoglobin in the bone marrow
ADE: NVD, HA, disorientation, chills, increase risk of cancer, bone marrow suppression
CI: allergy, severe anemia / leukopenia, pregnancy, liver/kidney impairment
, D-D: warfarin, uricosuric agents
epoetin alfa (Epogen), erythropoiesis stimulating agent - WHY: treat anemia of chronic disease, reduce
the need for pRBC transfusions
MOA: stimulates bone marrow to make more RBCs (erythropoiesis)
ADE: seizures, HA, dizzy, NVD, HTN, edema, chest pani
CI: uncontrolled HTN
D-D: do not mix with other drugs
antihemophilic - WHY: replace factor VIII in patients with hemophilia A, prevent blood loss from injury,
surgery or to treat disorder
MOA: replaced blood clotting factors - genetically missing or low
ADE: HA, flushing, chills, lethargy, NV, site reaction
CI: allergy, inhibitors of factor VIII, factor IX with liver disease, lactation
antiocoagulants - -prevents clots and prevents from getting bigger
-does not get rid of a clot
- heparin
- warfarin
heparin - - suppresses intrinsic pathway
- monitor PTT levels every ~4-6 hours
- IV: bolus then continuous drip; unfractional
- SQ: LMW, doesn't require monitoring of PTT levels at low doses
- inactivator: protamine sulfate
- therapeutic action within seconds
- dosing is weight based
low molecular weight heparins - - more predictable and longer half life
